[Media Releases] [Herald Economy] Brain Industry Report – LegoChem proves its prowess in novel drug research and development

Title: Brain Industry Report – LegoChem proves its prowess in novel drug research and development

Publication: Herald Economy / Jung-Hwan Lee

Date: 22 June 2015

Summary

•        LegoChem Biosciences (LCB) is a novel drug research and development company that has generated revenue solely from its technology since inception in 2006.

•        LCB’s CEO, formerly affiliated with LG Life Sciences, brings experiences from early drug discovery to US FDA approval. Other competitive experts in drug synthesis also comprise LCB.

•        LCB signed seven licensing and collaboration deals for six years after inception, both globally and nationally, was listed in the KOSDAQ in 2013, and was selected as the K-Brain company by the government in 2014.

•        The company’s short-term goal is to generate cash flows by global out-licensing to make sure the business has enough to survive, and eventually in the mid- and long-term, to become a global biopharmaceutical company by combining chemical and biological drugs to make its own novel drugs to thrive.  

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).